INTRODUCTION
Allograft vasculopathy is a major cause of late graft dysfunction following cardiac and possibly pulmonary and renal transplantation [1] [2] [3] . Despite advances made in controlling acute rejection, little progress has been made in treatment or prevention of allograft vasculopathy. Development of effective therapies for allograft vasculopathy requires a mechanistic understanding of its underlying pathogenesis, which remains incompletely defined. The origin of graft ischemia resulting from allograft vasculopathy is distinct from other atherosclerotic conditions (such as coronary artery disease) and as such, pharmacotherapies with demonstrable efficacy in atherosclerosis have little effect in prevention of allograft vasculopathy [4] .
An understanding of allograft vasculopathy pathogenesis has been limited in part due to a lack of relevant model systems. Data from rodent models may not accurately recapitulate human allograft vasculopathy because allograft vasculopathy lesions in many rodent models develop in response to acute graft vessel injury, and the resulting lesions are often composed of proliferating host-derived smooth muscle cells (SMCs). In contrast, human allograft vasculopathy lesions develop with little evidence of injury and are composed of graft-derived SMCs [5] [6] [7] . Furthermore, rodent endothelium is immunologically dissimilar to human endothelium, generally lacking expression of class II major histocompatibility complex (MHC) molecules as well as key costimulatory (e.g. CD58) and coinhibitory (e.g. CD273) molecules that regulate memory CD4 þ and CD8 þ T cells in vitro and in vivo [8] [9] [10] [11] . Experimental models must be shown to recapitulate features of human allograft vasculopathy to define clinically
ALLOGRAFT VASCULOPATHY DEFINED
In cardiac transplantation, in which allograft vasculopathy has been most extensively analyzed, clinically significant lesions most prominently affect the epicardial and intramyocardial arteries. At these sites, diffuse stenoses due to concentric intimal expansion and inadequate compensatory (outward) remodeling result in tissue malperfusion, ischemic injury and graft loss. The expanded intima consists of proliferating graft-derived SMCs, concentrated near the intimal-medial border and a collagen-rich extracellular matrix. The lumen of the affected arteries is lined by an intact, graftderived endothelial cell monolayer. A host-derived mononuclear cell infiltrate, consisting primarily of T cells and macrophages, localizes subadjacent to the luminal endothelial cells. Innate lymphoid cells and other myeloid cell types, such as dendritic cells, may also be present within the intima, albeit at low frequency compared with T cells and macrophages. The arterial media is largely normal in histologic appearance, whereas the adventitia may contain a chronic inflammatory infiltrate, sometimes with formation of tertiary lymphoid organs with B-cell follicles [12] .
CURRENT MODELS OF PATHOGENESIS
The presence of host T and B cells, the restriction of lesions to the graft vasculature, the lack of overt graft cell lysis and a time course of development over months to years collectively suggest that allograft vasculopathy is primarily a consequence of chronic alloimmunity [4] . Data from animal models and human tissues suggest that allograft vasculopathy is a form of T H 1-mediated delayed-type hypersensitivity (DTH) in which IFN-g production by alloreactive host T cells is driven by recognition of alloantigens, especially nonself polymorphic forms of class I and II MHC molecules, expressed on the surface of the graft-derived luminal endothelial cells [4] . Invasion of SMCs from the media or adventitia and local SMC proliferation likely underlie the intimal SMC accumulation. Importantly, human IFN-g is directly mitogenic for SMCs in the intima and media of isolated human coronary artery segments implanted as aortic interposition grafts in immunodeficient mouse hosts [13, 14] . Similar results may be observed using mouse IFN-g and wild-type mouse aortic grafts implanted into IFN-g receptor-deficient mouse hosts [15] . Furthermore, many T cells identified in clinical allograft vasculopathy lesions in the heart express IFN-g [16, 17] . IFN-g released by intimal infiltrating T cells also induces production of chemokines that attract additional T H 1 cells and monocytes as well as SMCs [18] . Additional mitogens may be produced by the infiltrates of host leukocytes or by graft cells, including endothelial cells.
The T H 1 chronic DTH model of allograft vasculopathy does not explain the adventitial inflammation that is linked to inadequate compensatory vascular remodeling. It also fails to explain why the majority of patients with allograft vasculopathy will have formed donor-specific antibodies (DSA), most often complement-fixing and directed toward a nonself allele of human leukocyte antigen (HLA)-DQ [19, 20] . The link to DSA, although not detected in all patients with allograft vasculopathy, has led some investigators to focus on the direct effects of DSA on the vessel wall as the primary driver of allograft vasculopathy [21, 22] . In support of this idea, mouse mAb reactive with human class I MHC antigens, like the effects of IFN-g, can produce allograft vasculopathy-like changes in human arteries transplanted into immunodeficient mouse hosts depleted of complement [23] . It is unclear in this model if the antibody causes vascular cell injury through complement activation and/or antibodydependent cell-mediated cytotoxicity or if the intimal expansion involves recruitment of host SMCs, as occurs following allotransplantation of arterial grafts into immunocompetent mouse hosts [7] . In support of a nonlytic DSA model, cultured endothelial cells respond to these same antibodies by activating signaling pathways that induce production and/or release of SMC mitogens [24, 25] .
KEY POINTS
Allograft vasculopathy is a major cause of late allograft loss and for which no therapies are available.
Experimental models reproducing the salient features of human allograft vasculopathy will increase the likelihood of uncovering clinically relevant pathogenic mechanism(s).
Innate immunity (NK cells and donor-derived macrophages) and adaptive immunity (T cells and B cells) are implicated in allograft vasculopathy.
Ongoing clinical trials involving proteasome and mTOR inhibitors are being evaluated for treatment and prevention of allograft vasculopathy.
However, an alternate possibility is that DSA and sublytic complement contribute to a T H 1 chronic DTH-like mechanism through alterations in graft endothelial cells that augment host T-cell release of IFN-g [4, 26] .
THE ROLES OF INNATE IMMUNE CELLS IN ALLOGRAFT VASCULOPATHY
Innate immune cells, including natural killer (NK) cells and macrophages, may serve as mediators of allograft vasculopathy. NK cells are a subset of type 1 innate lymphoid cells, a population that produces T H 1-like cytokines, especially IFN-g, and in the case of NK cells, may also mediate cytolysis. NK cells may be activated by cytokines or by engagement of germline-encoded activating receptors. Conversely, NK cells may be kept quiescent by engagement of inhibitory receptors or by regulatory T cells (T reg ) [27] . Severe combined immunodeficiency disease (SCID) mice, which lack T and B cells, can mount a strong NK cell response against infection but do not produce allograft vasculopathy lesions in cardiac allografts, suggesting that the effect of NK cells is dependent upon adaptive immunity [13] . The role of T cells in activating NK cells can be demonstrated in a mouse heterotopic heart transplant model [28] . Engagement of a DSA bound to graft endothelial cells by NK cells expressing activating low-affinity F c receptors (CD16) has also been proposed as a mechanism of allograft vasculopathy pathogenesis in these mouse models [29, 30] .
Following F c R engagement, macrophages may also play an important role in development of allograft vasculopathy through release of SMC mitogens [29] , and depletion of macrophages reduces allograft vasculopathy-like lesions in mouse heterotopic heart transplants [31] . Macrophages, like dendritic cells, may also release proinflammatory cytokines such as IL-12, which could induce type 1 innate lymphoid cells, including NK cells, as well as Th1 cells to produce IFN-g. The presence of macrophages within the graft is closely associated with worsened long-term outcomes in humans [32] [33] [34] . Macrophages may undergo classical activation in response to T H 1 cytokines (becoming 'M1' macrophages) or in response to other signals, undergoing alternative activation. Some alternatively activated states resemble macrophages found in T H 2-type inflammatory responses ('M2' macrophages) but many other patterns of alternative activation have also been described (and often mislabeled as M2). Significantly, the presence of alternatively activated macrophages within vascular inflammatory lesions is closely correlated with progressive allograft vasculopathy [35] .
New insights into the roles of innate immune cells in allograft vasculopathy from animal models
As noted above, NK cells in Rag gene knockout animals (which, like SCID mice, lack T and B cells) can induce chronic vasculopathy in a transplanted C3H/HeJ mouse heart following treatment with anti-MHC class I antibody. A recent study has shown that NK-mediated allograft vasculopathy in this model can be ameliorated with IFN-g neutralization, or simultaneous disruption of perforin and Fas expression [36 & ]. The latter finding suggests that this model may involve graft cell destruction followed by recruitment of host SMCs, which needs to be ruled out if the findings are to apply to human allograft vasculopathy. NK cells may also play a role in damping chronic inflammatory responses by killing donor-derived tissue-resident CD4 þ T cells that provide help to host B cells that produce DSAs [37 && ]. Graft-derived molecules including vanin [38] and Noctanoyl dopamine [39] may promote allograft vasculopathy by enhancing macrophage vessel infiltration and apoptosis of SMCs, respectively.
New insights into the roles of innate immune cells in allograft vasculopathy from human tissues
Studies in lung transplant patients have demonstrated that donor-derived tissue-resident macrophages persist within the allograft years following transplantation and play a key role in eliciting proinflammatory responses to DSA [40] . NK cell-mediated chronic inflammation has further been corroborated in human tissue samples that have closely correlated IL-6 and markers of endothelial cell activation [Vascular Cell Adhesion Molecule (VCAM)-1 and Intercellular Sdhesion Molecule-1] with allograft vasculopathy lesions [41] . In addition, association of intragraft NK cell infiltrates with capillary inflammation and tubulitis scores assessed on renal biopsy more than 1 year following transplantation has been noted [42] . The relationship of these microvascular changes to arterial allograft vasculopathy is not clearly understood. It is possible that microvascular changes in lung allografts, rather than arterial changes, are the driver of late graft loss for this organ.
THE ROLES OF ADAPTIVE IMMUNE CELLS IN ALLOGRAFT VASCULOPATHY
Adaptive immunity may be defined as responses to antigens mediated by T and B cells that express somatically generated antigen receptors. Host T-cell receptors for antigen may recognize nonself allelic forms of MHC molecules bound to a wide variety of different peptides (direct recognition) or may respond to peptides from nonself allelic forms of various graft proteins bound to self MHC (indirect recognition) expressed on the surface of a host antigen presenting cell. Host B cells, whose antigen receptors may recognize intact nonself MHC molecules on graft cells, can also serve as antigen presenting cells to T cells as well as sources of cytokines and of DSA. The anatomical site(s) of DSA production and presumptive affinity maturation of DSA-producing B cells, often detected in allograft vasculopathy lesions, is unknown [12] . Adventitial B cells represent one potential site.
Many investigations have focused on the role of DSA in allograft vasculopathy. In addition to engagement of F C receptors on innate immune cells, DSA directly triggers inflammatory signaling in both the graft endothelium and smooth muscle and also mediates classical complement activation. Crosslinking of DSA on endothelial cells elicits signaling pathways involved in cellular proliferation, stress fiber formation and mitogenic signaling [43] . Recent studies in humanized mouse models have revealed that direct binding of anti-HLA class I antibodies to human SMCs initiate mitogenic signaling and enhanced secretion of matrix metalloproteinases, contributing to development of allograft vasculopathy-like lesions [44] .
Complement fixation initiated by engagement of anti-HLA antibodies on endothelial cell additionally enhances graft immunogenicity. Deposition of the membrane attack complex (MAC) [45] triggers noncanonical NF-kB signaling, upregulating proteins that render the endothelium more immunogenic without directly causing cell death [26] . Moreover, anaphylatoxins (bioactive complement split products), potentiate T-cell activation [46] , T H 1 polarization [47] and endothelial cell activation [48] , although the relevance of these responses in allograft vasculopathy has not been established.
New insights into the roles of adaptive immunity in allograft vasculopathy from animal models
Studies in mouse models have affirmed the critical role of donor-reactive memory CD4 þ T cells in enhancing production of DSA by alloreactive B cells. In a MHC-mismatched rodent model of renal transplantation, recipients containing donor-reactive memory CD4 þ T cells rapidly lost allograft function in a manner dependent on B-cell alloantibody generation [49] . Mitigating the effects of DSA production by targeting B cells has also been attempted in mouse models. Although human B-cell depletion can be effectively mediated by anti-CD20 mAb, no mouse-equivalent reagent has been developed. However, mice expressing human CD20 have been generated, and a recent study found that despite effective depletion of B cells (and DSA) with early anti-human CD20 antibody treatment posttransplant, a rebound of high DSA titers occurred within 1 month with development of significant interstitial graft fibrosis [50 & ].
New insights into the roles of adaptive immunity in allograft vasculopathy from studies utilizing human cells and tissues
The close association of antibody-mediated rejection with allograft vasculopathy has been closely evaluated in explanted hearts from patients undergoing retransplantation for failing heart allografts [51] . Although substantial portion of failing cardiac allografts exhibited subclinical antibody-mediated rejection, the manner in which binding of DSA promotes chronic vascular inflammation has also been the subject of recent investigation. Anti-class I MHC antibody promotes HLA association with b 4 integrins to activate intracellular signaling cascades which in turn, upregulate leukocyte adhesion molecules, facilitating recruitment of neutrophils and monocytes [52] [53] [54] . Anti-HLA-DR antibodies can increase endothelial cell secretion of IL-6, thereby amplifying a proinflammatory response by enhancing T H 17 expansion diminishing functional T reg proliferation [55] . Although classically DSA targets have been anti-HLA antibodies, the presence of non-HLA antibodies is increasingly being recognized as correlated with chronic rejection and diminished long-term graft survival [56] . However, the mechanism by which such antibodies may influence allograft vasculopathy is unknown.
DSA-mediated activation of human SMC proliferation may also occur via generation of mitogenic sphingosine-1-phosphate (S1P), and a protective effect of an anti-S1P antibody was recently demonstrated both in vitro using cultured human SMCs and in vivo using a humanized arterial graft model [57 & ]. Recent work using human tissues has also elucidated the mechanism by which complement-fixing alloantibodies triggers noncanonical NF-kB signaling by internalizing the MAC within Rab5 þ endosomes, forming a unique intracellular signaling complex [58] . Interestingly, these effects have been shown to be attenuated with use of an anti-C5 but not an anti-C5a antibody, thereby implicating MAC-dependent signaling as a key mediator of endothelial activation [59 && ]. Such findings have the potential to be translated into new treatment strategies as has recently been demonstrated in the anti-C1s complement inhibitor, shown to abrogate complement-mediated activation of human aortic endothelial cells [60 && ]. Novel agents targeting the complement pathway like eculizumab are currently under investigation for use in patients at high risk for antibody-mediated rejection.
OTHER CONTRIBUTORS TO THE DEVELOPMENT OF ALLOGRAFT VASCULOPATHY
Other known risk factors for allograft vasculopathy include acute vascular rejection, perioperative ischemia-reperfusion injury (IRI) [25] or infection of the graft, particularly with cytomegalovirus (CMV). Recent data have demonstrated that many of these exposures trigger noncanonical NF-kB and innate immune pathways including high-mobility group box 1 (HMGB1) and MyD88 that enhance development of allograft vasculopathy [61] . Some investigators have proposed that allograft vasculopathy results from the sum of these insults ('burden of injury' model) [25] .
Ischemia-reperfusion injury
IRI results from cellular necrosis and sterile inflammation following surgical implantation, often manifesting in delayed graft function [25] . Complement activation is closely associated with IRI, inducing MAC formation on the surface of the graft endothelium that ultimately results in enhanced endothelial immunogenicity mediated by activation of noncanonical NF-kB signaling. Blockade of MAC deposition through the administration of anti-C5 antibody has been recently demonstrated to result in attenuated noncanonical NF-kB signaling and diminished formation of stenotic and thrombotic allograft vasculopathy in human coronary arteries implanted into SCID/bg mice that had previously received adoptive transfer of human T cells allogeneic to the artery [59 && ]. In addition to complement-mediated IRI, recent work has demonstrated that the upregulation of HMGB1 protein may further enhance endothelial activation by activation of Toll-like receptor (TLR) 4 and MyD88 signaling [62] . Blockade of HMGB1 and each of these downstream effectors correlated with reduced ischemic damage, implicating its role as an enhancer of ischemia-induced vascular inflammation [63] .
Cytomegalovirus infection
Infection with CMV has been recognized as a significant risk factor for allograft vasculopathy. A recent large retrospective study in patients following long-term heart transplantation demonstrated that those with either asymptomatic or symptomatic CMV infection had significantly increased allograft vasculopathy and reduced 10-year graft survival [64] . Although the exact mechanism in which CMV infection leads to allograft vasculopathy has not been elucidated, the ability of subclinical infection to directly activate graft endothelium or enhance innate immune responses are two mechanisms that have been proposed [4] . CMV readily infects endothelial cells without causing their death and in this manner may effectively increase CD4 þ Tcell reactivity to infected endothelium, contributing to a T H 1-like chronic DTH [65] .
Immunosuppressive pharmacotherapy
Recent reports have implicated TLR pathways in vascular injury rendered by use of chronic immunosuppressants. Calcineurin inhibitors, among the most commonly used immunosuppressants for prevention of acute rejection, contribute to the development of allograft vasculopathy, hypertension and atherosclerosis. A recent report has shown that activation of TLR4 by these agents contributes to the enhancement NF-kB signaling, resulting in upregulation of adhesion molecules, chemokine expression and production of reactive oxygen species in both cultured and aortic endothelial cells as well as vascular SMCs [66 & ]. These findings provide mechanistic insight for vascular inflammation induced with chronic calcineurin inhibitor use and support the investigation of adjuvant therapies or calcineurin inhibitor-free regimens for maintenance of immunosuppression.
NEW INSIGHTS INTO CAUSES OF ALLOGRAFT VASCULOPATHY FROM CLINICAL TRIALS
The central role of DSA in enhancing allograft vasculopathy has led to clinical trials aimed at targeting plasma cells, a potential source of DSA not affected by B-cell depletion. Recent trials with bortezomib, a proteasome inhibitor that is toxic for plasma cells, in children undergoing renal transplantation with high HLA mismatch and biopsy-proven antibodymediated rejection was well tolerated and demonstrated stabilization of renal function [67] . Larger randomized trials evaluating the effectiveness of this agent in enhancing longer term posttransplant renal function are currently in progress [68 & ]. Proliferation of SMCs, like that of T cells, may be inhibited by mammalian target of rapamycin (mTOR) inhibitors, and this is the basis of their use in coated stents. More recently, it has been appreciated that these agents also affect antigen-presenting cells, including dendritic cells and vascular endothelial cells [69] . mTOR inhibitor-treated endothelial cells lose the ability to activate IFN-g production by alloreactive CD4
þ T H 1 cells but retain the capacity to activate T regs [70] . In humanized mouse models, mTOR inhibitors can increase the ability of T regs to protect human artery grafts from intimal T-cell infiltration and injury [71] . Everolimus, a rapamycin-like mTOR inhibitor coupled with elimination of calcineurin inhibitor immunosuppression, demonstrated a reduction in progression of allograft vasculopathy in heart-transplant patients [72 & ]. Notably however, no effect of the NF-kB products including IL-6 and VCAM-1 was noted in graft endothelium, suggesting that either clinical observations may be inconsistent with mechanisms noted in human cells or that the observed clinical improvement, may in part, arise from calcineurin-inhibitor withdrawal.
CONCLUSION
Allograft vasculopathy, a form of chronic rejection, is a major cause of late graft loss, limiting the longevity of heart, and likely renal and lung allografts. Recent experimental studies have continued to explore pathogenesis using animal models as well as analyses of human cells and tissues. Such investigations support the roles of both innate and adaptive immune cells in the pathogenesis of allograft vasculopathy. Although currently there are no effective treatments, mechanistic hypotheses arising from experimental models are currently being evaluated in clinical trials.
